Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Shock
Description
A pathological condition manifested by failure to perfuse or oxygenate vital organs. MeSH
Hierarchy View
Subtype Terms (6)
Multiple Organ Failure
30 drugs (20 approved, 10 experimental)
Shock, Cardiogenic
32 drugs (23 approved, 9 experimental)
Shock, Hemorrhagic
18 drugs (12 approved, 6 experimental)
Shock, Surgical
1 approved drug
Shock, Traumatic
8 drugs (4 approved, 4 experimental)
Systemic Inflammatory Response Syndrome
52 drugs (32 approved, 20 experimental)
Approved Indicated Drugs (5)
Phase 4 Indicated Drugs (15)
Phase 1 Indicated Drugs (2)
Other Experimental Indicated Drugs (9)
Organization Involved with Phase 4 Indications (57)
Association Niçoise de Réanimation Médicale
Australian and New Zealand Intensive Care Society Clinical Trials Group
Centre Hospitalier Universitaire de Nīmes
Hoosier Cancer Research Network
Hospital Universitario Ramon y Cajal
Institute of Liver and Biliary Sciences, India
Laboratoire français de Fractionnement et de Biotechnologies
La Jolla Pharmaceutical Company
Methodist Cancer Center, Houston, Texas
National Center for Advancing Translational Science (NCATS)
National Center for Research Resources (NCRR)
National Health and Medical Research Council, Australia
Organization Involved with Phase 3 Indications (124)
American British Cowdray Medical Center
A.O. Ospedale Maggiore di Lodi
AOU S. Luigi Gonzaga, Orbassano
Aragon Institute of Health Sciences
Assistance Publique - Hôpitaux de Paris
Baqiyatallah Medical Sciences University
Bataillon des marins pompiers de Marseille, France
Canadian Critical Care Trials Group
Canadian Institutes of Health Research (CIHR)
Case Western Reserve University
Centre Hospitalier de Cherbourg
Centre Hospitalier de Tourcoing
Centre Hospitalier de Valenciennes
Centre Hospitalier Régional d'Orléans
European Society of Intensive Care Medicine
German Federal Ministry of Education and Research
Hamadan University of Medical Science
Hôpital Saint Philibert, Lomme
Hospital center of Annecy Genevois,France
Hospital de St. António dos Capuchos
Institut de Recherche Biomedicale des Armees
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
National Heart, Lung, and Blood Institute (NHLBI)
National Hepatology & Tropical Medicine Research Institute
National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health (NIH)
People's Liberation Army of China
Sepsis Occurrence in Acutely Ill Patients
Organization Involved with Phase 2 Indications (78)
Autonomous University of Madrid
Biomedizinische Forschungs gmbH
Boryung Pharmaceutical Company
Gottfried Wilhelm Leibniz Universität Hannover
Hamilton Health Sciences Corporation
Institut National de la Santé Et de la Recherche Médicale, France
Iuliu Hatieganu University of Medicine and Pharmacy
Jinhua municipal central hospital
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Ontario Institute for Regenerative Medicine (OIRM)
San Juan Batista Medical School
Spanish National Health System
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (39)
Fundação de Amparo à Pesquisa do Estado de São Paulo
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
